Janus Henderson Group
TRDA icon

Janus Henderson Group’s Entrada Therapeutics TRDA Stock Holding History

Janus Henderson Group’s Portfolio TRDA Stock Details TRDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-1,521,281
Closed -$10.2M – 2472
2025
Q2 		$10.2M Sell
1,521,281
-600,373
-28% -$4.83M 0.01% 717
2025
Q1 		$20.3M Buy
2,121,654
+41,287
+2% +$514K 0.01% 570
2024
Q4 		$36M Buy
2,080,367
+368,908
+22% +$6.68M 0.02% 450
2024
Q3 		$27.4M Buy
1,711,459
+161,962
+10% +$2.55M 0.01% 511
2024
Q2 		$22.1M Buy
+1,549,497
New +$22M 0.01% 542

Other funds holding TRDA

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MC
Merck & Co Rahway, New Jersey $526M AUM 175.27% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
SG
StepStone Group La Jolla, California $2.16B AUM 20.11% 1-Year Est. Return
CF
Cantor Fitzgerald New York $9.31B AUM 73.66% 1-Year Est. Return

Janus Henderson Group's TRDA Position: Q3 2025 in Review

Janus Henderson Group sold out of Entrada Therapeutics (TRDA) in Q3 2025, closing a stake of 1,521,281 shares — an estimated $10.2M sold.

Janus Henderson Group first reported a position in TRDA in Q2 2024 and held it in 5 quarters. The position peaked at $36M in Q4 2024. 117 funds tracked by Wall St. Rank hold TRDA as of Q3 2025.

  • Janus Henderson Group reported no remaining Entrada Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Janus Henderson Group sold 1,521,281 Entrada Therapeutics shares in Q3 2025, an estimated $10.2M.
  • Janus Henderson Group first reported a position in Entrada Therapeutics in Q2 2024 and held it in 5 quarters.
  • Janus Henderson Group's Entrada Therapeutics position peaked at $36M in Q4 2024.
  • 117 funds tracked by Wall St. Rank held Entrada Therapeutics as of Q3 2025.

Based on Janus Henderson Group's 13F filing for Q3 2025, filed 14 Nov 2025.